Drug Profile
CNTO 528
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Centocor
- Class Antianaemics
- Mechanism of Action Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Anaemia in USA
- 17 Jan 2006 Phase-I clinical trials in Anaemia in USA (unspecified route)